Shockwave Medical
Revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque.
Launch date
Employees
Market cap
€11.4b
Enterprise valuation
€11.0b (Public information from Jun 2024)
Share price
$334.79 SWAV
Company register number HRB 14070 (Kleve)
Santa Clara California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 67.8m | 237m | 490m | 730m | 921m | 1.1b | 1.4b |
| % growth | 58 % | 250 % | 107 % | 49 % | 26 % | 23 % | 21 % |
| EBITDA | (64.4m) | (7.7m) | 123m | 192m | 263m | 350m | 427m |
| % EBITDA margin | (95 %) | (3 %) | 25 % | 26 % | 29 % | 31 % | 31 % |
| Profit | (65.7m) | (9.1m) | 216m | 147m | 187m | 243m | 302m |
| % profit margin | (97 %) | (4 %) | 44 % | 20 % | 20 % | 21 % | 22 % |
| EV / revenue | 49.7x | 25.8x | 14.6x | 9.3x | 12.9x | 11.1x | 9.2x |
| EV / EBITDA | -52.3x | -789.8x | 58.3x | 35.4x | 45.2x | 35.9x | 29.4x |
| R&D budget | 36.9m | 50.5m | 81.7m | 146m | - | - | - |
| R&D % of revenue | 54 % | 21 % | 17 % | 20 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$12.5m | Series A | ||
$40.0m | Series B | ||
$45.0m | Series C | ||
$35.0m | Series C | ||
$15.0m | Series D | ||
| N/A | $97.0m Valuation: $457m 37.3x EV/LTM Revenues -11.4x EV/LTM EBITDA | IPO | |
$89.0m Valuation: $1.5b 33.9x EV/LTM Revenues -29.4x EV/LTM EBITDA | Secondary | ||
* | N/A | $650m | Post IPO Convertible |
* | $8.8m | Post IPO Equity | |
* | $13.1b Valuation: $13.1b 17.9x EV/LTM Revenues 68.4x EV/LTM EBITDA | Acquisition | |
| Total Funding | €134m | ||
